Clovis Oncology Inc
Latest Clovis Oncology Inc News and Updates

Analysts’ Recommendations for Bristol-Myers Squibb in August 2017
Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

Gauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.

Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

Is Rising Consumer Sentiment Helping the Market Rally in 2017?
The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.

IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

Dyax Traded above Its 100-Day Moving Average
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.